Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the <scp>UK</scp> setting

Abstract

Long-term projections suggest that treatment of patients with type 2 diabetes with liraglutide 1.8 mg is likely to be considered highly cost-effective compared with lixisenatide 20 µg treatment in the UK setting.